Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: A retrospective cohort study

Arthritis Care and Research

Volumn 67, Issue 4, 2015, Pages 457-466

  Desai, Rishi J ^a   Eddings, Wesley ^a   Liao, Katherine P ^b   Solomon, Daniel H ^a   Kim, Seoyoung C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTILIPEMIC AGENT; AURANOFIN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHOLESTEROL; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; GOLIMUMAB; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TRIACYLGLYCEROL; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DRUG USE; FEMALE; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; FOLLOW UP; HYPERLIPIDEMIAS; INCIDENCE; RISK FACTOR;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84925455998     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22483     Document Type: Article

References (42)

1. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JA, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303.
3. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR,. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93: 198-200.
4. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69: 1920-5.
5. Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE,. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008; 58: 2268-74.
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB,. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
7. Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE,. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1310-4.
8. Liao KP, Cai T, Gainer VS, Cagan A, Murphy SN, Liu C, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken) 2013; 65: 2046-50.
9. Boyer JF, Bongard V, Cantagrel A, Jamard B, Gottenberg JE, Mariette X, et al. Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: results from a French multicenter cohort. Arthritis Care Res (Hoboken) 2012; 64: 872-80.
10. Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M,. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis 2010; 69: 741-6.
11. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA,. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-7.
12. Morris SJ, Wasko MC, Antohe JL, Sartorius JA, Kirchner HL, Dancea S, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011; 63: 530-4.
13. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA,. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-6.
14. Seriolo B, Fasciolo D, Garnero A, Accardo S,. The influence of hydroxychloroquine, methotrexate and the combination of both on lipid profile in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1999; Suppl 9: S81.
15. Kerr G, Aujero M, Richards J, Sayles H, Davis L, Cannon G, et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken) 2014; 66: 1619-26.
16. Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD, et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008; 38: 13-9.
17. Navarro-Millan I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013; 65: 1430-8.
18. Van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA, et al. The effect of TNF-α blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2011; 41: 393-400.
19. Curtis JR, John A, Baser O,. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2012; 64: 1282-91.
20. Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303: 1401-9.
21. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S,. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-31.
22. Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009; 219: 7-21.
23. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM,. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110: 587-93.
24. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD,. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125: e208-13.
25. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011; 13: R32.
26. Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, et al. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol 2012; 12: 180.
27. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S,. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011; 64: 749-59.
28. Allison PD,. Survival analysis using SAS: a practical guide. 2nd ed. Cary (NC): SAS Institute; 2012.
29. Sturmer T, Rothman KJ, Avorn J, Glynn RJ,. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution. A simulation study. Am J Epidemiol 2010; 172: 843-54.
30. Morgan SL, Winship C,. Counterfactuals and causal inference: methods and principles for social research. Cambridge (UK): Cambridge University Press; 2007.
31. Sica GT,. Bias in research studies. Radiology 2006; 238: 780-9.
32. Beynen AC, van der Molen AJ, Geelen MJ,. Inhibition of hepatic cholesterol biosynthesis by chloroquine. Lipids 1981; 16: 472-4.
33. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J,. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997; 3: 3-8.
34. Cairoli E, Rebella M, Danese N, Garra V, Borba EF,. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012; 21: 1178-82.
35. Daien CI, Duny Y, Barnetche T, Daures JP, Combe B, Morel J,. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012; 71: 862-8.
36. Choy E, Sattar N,. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460-9.
37. Jamnitski A, Visman IM, Peters MJ, Dijkmans BA, Voskuyl AE, Nurmohamed MT,. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis 2010; 69: 1929-33.
38. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
39. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK,. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1495-8.
40. Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF α blockade with nonbiologic DMARDs. Am J Med 2013; 126: 730.
41. Ray WA,. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
42. Psaty BM, Siscovick DS,. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA 2010; 304: 897-8.